Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Henry Niman who wrote (16651)	3/6/1998 9:06:00 PM
From: Pseudo Biologist	Read Replies (1) \| Respond to of 32384

Thanks Henry. If you want more on Wild Bill get a load of this: washingtonpost.com Now, on that tail ... Are you saying two of Ligand's partners may merge to be more efficient in "milking" STATs/IRs? Or is Ligand an M&A target? What are you trying to say here? I see the trees in your tale but cannot see the forest just yet. PB

To: Henry Niman who wrote (16651)	3/6/1998 9:59:00 PM
From: WTDEC	Respond to of 32384

Henry, thanks for producing this post. For me, it is one of the most important I've seen on this thread. I have long been mulling a concern that I wanted to you ask about, but couldn't clearly spell it out. I was concerned that combinatorial chemistry and genomics might technologically 'leap frog' LGND. Based on what your post outlines, LGND seems way out front and cc/genomics are not likely to threaten LGND's discoveries. I'm a lot more comfortable now, but any elaboration on this point would be welcome. Regards, wtd